Blueprint Medicines gains on Sanofi's $9 bln buyout offer
View all comments(0)
Blueprint Medicines BPMC.O jumps 27.03% to $128.74 premarket
French drugmaker Sanofi SASY.PA to buy Blueprint for more than $9 billion
Sanofi paying $129/share in cash for Blueprint, a 27% premium to last close
Deal's equity value ~$9.1 billion, with potential to increase to $9.5 billion, including contingent value rights
Acquisition expected to be finalized in Q3 2025
BPMC up 16.2% this year, as of last close
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Rocket Lab Earnings Greatly Exceed Expectations, Ignoring Risks as Stock Price Surges?

Tradingkey






Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.